Apple Watch-guided event-triggered anticoagulation reduced DOAC exposure by 94.6% compared with continuous anticoagulation in post-ablation atrial fibrillation patients, with no thromboembolic events.
Does an Apple Watch-guided event-triggered anticoagulation strategy reduce DOAC exposure in postablation atrial fibrillation patients with a CHA2DS2-VASc score ≤3?
An Apple Watch-guided event-triggered anticoagulation strategy safely and markedly reduced DOAC exposure by 94.6% in postablation AF patients with low-to-moderate stroke risk.
Effect estimate: 94.6% reduction (95% CI 89.8-98.4)
Absolute Event Rate: 5.4% vs 100%
Background: Continuous anticoagulation guided by the CHA2DS2-VASc score is standard for atrial fibrillation (AF) but does not reflect real-time AF occurrence. We evaluated an Apple Watch-guided event-triggered anticoagulation strategy that adjusts direct oral anticoagulant (DOAC) use according to smartwatch detection.
The Up to AF trial demonstrates that an Apple Watch-guided strategy significantly reduces DOAC exposure after AF ablation without thromboembolic events, sparking debate on wearable-driven therapy.
Sunaga et al. (Thu,) conducted a other in Atrial fibrillation post-ablation (n=54). Apple Watch-guided event-triggered anticoagulation vs. Continuous anticoagulation was evaluated on Percentage reduction in total DOAC days between Days 31 and 360 (94.6% reduction, 95% CI 89.8-98.4). Apple Watch-guided event-triggered anticoagulation reduced DOAC exposure by 94.6% compared with continuous anticoagulation in post-ablation atrial fibrillation patients, with no thromboembolic events.